Pharmaceutical Sciences
Global

Pharmaceutical Sciences Experts

Stephen Lam

Chief Medical Officer
R&D
Omnitura Therapeutics
United States of America

Biography

Stephen Lam, M.D., is a doctor of pulmonary medicine and is also Professor of Medicine at the University of British Columbia. Dr. Lam also serves as Chairman of the Lung Tumour Group at the BC Cancer Agency. He has served on the advisory committees at the U.S. Department of Health and the National Cancer Institute in functional imaging, biomarkers and chemoprevention committees. He was the past president of the International Photodynamic Association, Regent of the World Association of Bronchology, and Governor of the American College of Chest Physicians in British Columbia. He is the principal investigator of several U.S. NCI sponsored Phase I and Phase II clinical trials of chemopreventive agents that include both prescription drugs and natural products. He has published over 150 peer-reviewed articles, 11 patents and 27 book chapters. He is recognized as one of the world’s leading experts in early lung cancer detection and chemoprevention. Dr. Lam is also internationally recognized for his 25 years of scientific research in early lung cancer detection and chemoprevention. He is the co-inventor of the autofluorescence bronchoscopic device for localization of pre-neoplastic lesions and early lung cancer. The technology has been adopted by major endoscope companies worldwide. In 1999, he was the recipient of the Friesen-Rygiel Award for Outstanding Canadian Academic Discovery. In 2002, he was awarded the Gustav Killian Medal by the World Association of Bronchology for his pioneering contributions to the field of early lung cancer diagnosis. In 2007, he became the first MDS-Rix endowed Director of Early Lung Cancer Detection and Translational Research at the BC Cancer Agency. In 2008, he received the Distinguished Achievement Award and the Martin M. Hoffman Award for research excellence from the University of British Columbia. In 2008, Dr. Lam and his colleagues discovered a novel blood biomarker for early detection and surveillance of lung cancer after treatment—this marker is part of the multi-center Terry Fox Research Institute Pan-Canadian Early Lung Cancer Detection Study testing a multi-modal model to identify smokers at highest risk of lung cancer for combined spiral CT scan and autofluorescence bronchoscopy. In 2009, the International Association for the Study of Lung Cancer (IASLC) recognized Dr. Lam with the Joseph W. Cullen Award for life-time scientific achievements in prevention research of thoracic malignancies. Stephen Lam, M.D., is a doctor of pulmonary medicine and is also Professor of Medicine at the University of British Columbia. Dr. Lam also serves as Chairman of the Lung Tumour Group at the BC Cancer Agency. He has served on the advisory committees at the U.S. Department of Health and the National Cancer Institute in functional imaging, biomarkers and chemoprevention committees. He was the past president of the International Photodynamic Association, Regent of the World Association of Bronchology, and Governor of the American College of Chest Physicians in British Columbia. He is the principal investigator of several U.S. NCI sponsored Phase I and Phase II clinical trials of chemopreventive agents that include both prescription drugs and natural products. He has published over 150 peer-reviewed articles, 11 patents and 27 book chapters. He is recognized as one of the world’s leading experts in early lung cancer detection and chemoprevention. Dr. Lam is also internationally recognized for his 25 years of scientific research in early lung cancer detection and chemoprevention. He is the co-inventor of the autofluorescence bronchoscopic device for localization of pre-neoplastic lesions and early lung cancer. The technology has been adopted by major endoscope companies worldwide. In 1999, he was the recipient of the Friesen-Rygiel Award for Outstanding Canadian Academic Discovery. In 2002, he was awarded the Gustav Killian Medal by the World Association of Bronchology for his pioneering contributions to the field of early lung cancer diagnosis. In 2007, he became the first MDS-Rix endowed Director of Early Lung Cancer Detection and Translational Research at the BC Cancer Agency. In 2008, he received the Distinguished Achievement Award and the Martin M. Hoffman Award for research excellence from the University of British Columbia. In 2008, Dr. Lam and his colleagues discovered a novel blood biomarker for early detection and surveillance of lung cancer after treatment—this marker is part of the multi-center Terry Fox Research Institute Pan-Canadian Early Lung Cancer Detection Study testing a multi-modal model to identify smokers at highest risk of lung cancer for combined spiral CT scan and autofluorescence bronchoscopy. In 2009, the International Association for the Study of Lung Cancer (IASLC) recognized Dr. Lam with the Joseph W. Cullen Award for life-time scientific achievements in prevention research of thoracic malignancies.

Research Interest

marketing and sales

Global Experts from United States of America

Global Experts in Subject

Share This Profile